Erbium Glass, YAG Lasers Show Short-Term Efficacy for Rejuvenation and Acne
Non-ablative fractional erbium glass and ablative fractional erbium YAG laser therapies seem promising in the short term, with minimal adverse effects.
Non-ablative fractional erbium glass and ablative fractional erbium YAG laser therapies seem promising in the short term, with minimal adverse effects.
Two experts review their treatment strategies for addressing urticaria in their patients.
The New Drug Application for berotralstat for the prevention of hereditary angioedema attacks has been submitted to the Food and Drug Administration.
The Company filed the sBLA last November following FDA feedback on two completed Phase 2 trials of Ruconest for prophylaxis of HAE attacks.
The approval was based on data from 4 clinical trials, including the 26-week Phase 3 HELP (Hereditary Angioedema Long-Term Prophylaxis) study that enrolled 125 patients with HAE aged ≥12 years.
ADVM-053 is being developed as a single‑administration treatment that could potentially provide sustained levels of the C1 esterase inhibitor protein, which may prevent breakthrough angioedema attacks.